Table 2.
Patient characteristics
| Sensitivity testing | A | B1 | B2 | Subtotal of patients in B (B1 + B2) | All patients |
|---|---|---|---|---|---|
| Not performed | Performed | ||||
| Sensitive to paclitaxel | Insensitive to paclitaxel | ||||
| Treatment | Paclitaxel | Paclitaxel | FEC100 | ||
| No. randomized patients | 19 | 11 | 56 | 67 | 86 |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
| Median age | 50 | 57.0 | 52.0 | 53.0 | 52.5 |
| T | |||||
| T2 | 14 (74) | 8 (73) | 48 (86) | 56 (84) | 70 (81) |
| T3 | 4 (21) | 3 (27) | 5 (9) | 8 (12) | 12 (14) |
| T4 | 1 (5) | 0 (0) | 3 (5) | 3 (4) | 4 (5) |
| Median size (cm) | 3.6 | 4.2 | 3.6 | 3.8 | 3.75 |
| Range (cm) | 3.0–5.7 | 3.0–5.8 | 3.0–9.9 | 3.0–9.9 | 3.0–9.9 |
| N | |||||
| 0 | 7 (37) | 4 (36) | 24 (43) | 28 (42) | 35 (41) |
| 1 | 11 (58) | 6 (55) | 31 (55) | 37 (55) | 48 (56) |
| 2 | 1 (5) | 1 (9) | 1 (2) | 2 (3) | 3 (3) |
| Stage | |||||
| IIA | 7 (37) | 4 (36) | 25 (45) | 29 (43) | 36 (42) |
| IIB | 7 (37) | 4 (36) | 23 (41) | 27 (40) | 34 (40) |
| IIIA | 4 (21) | 3 (27) | 6 (11) | 9 (13) | 13 (15) |
| IIIB | 1 (5) | 0 (0) | 2 (3) | 2 (3) | 3 (3) |
| Histology | |||||
| Invasive ductal carcinoma | |||||
| Papillotubular carcinoma | 3 (16) | 0 (0) | 4 (7) | 4 (6) | 7 (8) |
| Solid tubular carcinoma | 4 (21) | 6 (55) | 11 (20) | 17 (25) | 21 (24) |
| Scirrhous carcinoma | 11 (58) | 5 (45) | 40 (71) | 45 (67) | 56 (65) |
| Others | 1 (5) | 0 (0) | 1 (2) | 1 (1) | 2 (2) |
| Nuclear grade | |||||
| 1 | 10 (53) | 1 (9) | 34 (61) | 35 (52) | 45 (52) |
| 2 | 5 (26) | 3 (27) | 11 (20) | 14 (21) | 19 (22) |
| 3 | 4 (21) | 7 (64) | 10 (18) | 17 (25) | 21 (24) |
| Undetermined | 0 (0) | 0 (0) | 1 (2) | 1 (1) | 1 (1) |
| Estrogen receptor | |||||
| Positive | 12 (63) | 2 (18) | 47 (84) | 49 (73) | 61 (71) |
| Negative | 7 (37) | 9 (82) | 9 (16) | 18 (27) | 25 (29) |
| Progesterone receptor | |||||
| Positive | 10 (53) | 0 (0) | 30 (54) | 30 (45) | 40 (47) |
| Negative | 9 (47) | 11 (100) | 26 (46) | 37 (55) | 46 (53) |
| HER2 | |||||
| Positive (IHC 3+ or FISH+) | 6 (32) | 4 (36) | 8 (14) | 12 (18) | 18 (21) |
| Negative | 13 (68) | 7 (64) | 48 (86) | 55 (82) | 68 (79) |
| Intrinsic subtype | |||||
| Luminal A | 10 (53) | 2 (18) | 43 (77) | 45 (67) | 55 (64) |
| Luminal B | 3 (16) | 0 (0) | 4 (7) | 4 (6) | 7 (8) |
| HER2 subtype | 3 (16) | 4 (36) | 4 (7) | 8 (12) | 11 (13) |
| Triple negative | 3 (16) | 5 (45) | 5 (9) | 10 (15) | 13 (15) |
FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor type 2; IHC, immunohistochemistry.